These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3149455)

  • 1. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients.
    Klioze SS; Miller MF; Spiro TP
    Am J Clin Oncol; 1988; 11 Suppl 2():S176-82. PubMed ID: 3149455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS
    Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate.
    Huben RP; Murphy GP
    Cancer; 1988 Nov; 62(9):1881-7. PubMed ID: 3139279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
    Peeling WB
    Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.
    Rajfer J; Handelsman DJ; Crum A; Steiner B; Peterson M; Swerdloff RS
    Fertil Steril; 1986 Jul; 46(1):104-10. PubMed ID: 3087785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C; Denis L
    Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial.
    Citrin DL; Resnick MI; Guinan P; al-Bussam N; Scott M; Gau TC; Kennealey GT
    Prostate; 1991; 18(2):139-46. PubMed ID: 1826048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
    Ryan PG; Peeling WB
    Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
    Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
    Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine treatment of prostate cancer.
    Turkes AO; Griffiths K
    Prog Med Chem; 1989; 26():299-321. PubMed ID: 2532376
    [No Abstract]   [Full Text] [Related]  

  • 13. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group".
    Bruun E; Frimodt-Møller C
    Scand J Urol Nephrol; 1996 Aug; 30(4):291-7. PubMed ID: 8908651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of prostatic cancer with LH-RH analogues.
    Borgmann V; Nagel R; Al-Abadi H; Schmidt-Gollwitzer M
    Prostate; 1983; 4(6):553-68. PubMed ID: 6415628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.
    Emtage LA; Trethowan C; Kelly K; Arkell D; Wallace DM; Hughes M; Hay A; Blacklock R; Jones M; Rouse A
    Prog Clin Biol Res; 1989; 303():47-52. PubMed ID: 2528739
    [No Abstract]   [Full Text] [Related]  

  • 18. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
    Faure N; Lemay A; Laroche B; Robert G; Plante R; Jean C; Thabet M; Roy R; Fazekas AT
    Prostate; 1983; 4(6):601-24. PubMed ID: 6415632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
    Chang A; Yeap B; Davis T; Blum R; Hahn R; Khanna O; Fisher H; Rosenthal J; Witte R; Schinella R; Trump D
    J Clin Oncol; 1996 Aug; 14(8):2250-7. PubMed ID: 8708714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome.
    Koutsilieris M; Tolis G
    Prostate; 1985; 7(1):31-9. PubMed ID: 3936031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.